Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have been updated to officially include Anktiva (generic name: N-803) in combination with BCG as a treatment option for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients presenting solely with papillary disease.

ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have been updated to officially include Anktiva (generic name: N-803) in combination with BCG as a treatment option for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients presenting solely with papillary disease.

老虎证券老虎证券2026/03/17 11:48
Show original
This guideline update marks a critical step forward in the clinical application of this combination therapy, providing a new treatment pathway for patients with specific types of bladder cancer. As an important reference standard in the field of oncology treatment, NCCN guidelines often have a profound impact on clinical practice and insurance coverage.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Sources say Southwest Airlines is considering adopting Boeing 787 to expand international long-haul routes

Sources say Southwest Airlines is considering adopting the Boeing 787 model to expand its international long-haul route business.

智通财经•2026/10/08 22:21

SpaceX acquires low-frequency spectrum, targeting US wireless carriers

SpaceX rose nearly 3% after hours as the company acquired low-frequency spectrum, targeting US wireless carriers.

智通财经•2026/10/08 22:16
SpaceX acquires low-frequency spectrum, targeting US wireless carriers

TD Bank approved for up to 100 billions CAD share repurchase plan

TD Bank has received approval to carry out a share repurchase program with a maximum amount of 10 billions Canadian dollars. This approval reflects TD Bank’s strong confidence in its own long-term fundamentals, and the bank will flexibly arrange the specific pace of the repurchase based on factors such as market conditions and its own operations.

智通财经•2026/10/08 22:16

SpaceX to acquire nationwide 800MHz spectrum portfolio pending FCC approval

SpaceX (SPCX.US) announced on Thursday that it has reached an agreement to acquire a portfolio of low-frequency spectrum licenses covering the entire United States, enabling it to directly compete with traditional wireless communication giants nationwide. While Starlink Mobile’s existing global 2 GHz mid-band spectrum will provide high bandwidth capacity, this new spectrum will allow its signals to penetrate obstacles. This move accelerates Elon Musk’s ambitious plan to bypass traditional wireless infrastructure and deliver cellular network connectivity directly to smartphones from Earth’s orbit. The deal involves acquiring 100% of a nationwide 800 MHz spectrum portfolio owned by private equity firm Grain Management, and is still subject to regulatory approval by the Federal Communications Commission (FCC). In addition, the FCC this week approved Starlink Mobile’s application for a second-generation satellite constellation, authorizing SpaceX to deploy 15,000 satellites worldwide optimized for the 2 GHz band. Following the announcement, shares of US telecom companies fell in after-hours trading, while SpaceX (SPCX.US) shares rose by over 1.7%.

智通财经•2026/10/08 21:36